ADIL — Adial Pharmaceuticals Share News
0.000.00%
Brief: Adial Pharmaceuticals Receives Final Reimbursement Payment From Adovate
Brief: Adial Pharmaceuticals Q3 net income USD -1.4 million
Brief: Adial Pharmaceuticals Announces $4 Mln Private Placement Priced At-The-Market Under Nasdaq Rules
Brief: Adial Pharmaceuticals Awarded Notice Of Allowance For Key Patent Combining Use Of The Company’S Proprietary Genetic Diagnostic With Ad04 To Treat Alcohol And Drug Dependence
Brief: Adial Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
Adial Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Adial Pharmaceuticals Inc expected to post a loss of $1.50 a share - Earnings Preview
Adial Pharmaceuticals Inc expected to post a loss of $1.50 a share - Earnings Preview
Brief: Adial Pharmaceuticals Announces Reverse Stock Split
Brief: Adial Provides Business Update Following Comments From US, EU Regulatory Meetings
Brief: Adial Pharmaceuticals Inc - Nasdaq Granted Co Extension Up Until Aug 21 To File A Form 10-Q
Brief: Adial Pharmaceuticals Inc Files With SEC For Resale Of Up To 10.2 Mln Common Shares By Alumni Capital LP
Brief: Adial Pharmaceuticals Received Notice Of Delisting From Nasdaq
Adial Pharmaceuticals Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Adial Pharmaceuticals Receives Notice Of Exercise From Adovate For Acquisition Of Purnovate’S Assets
U.S. STOCKS ON THE MOVE-BlackSky, Squarespace, Virax Biolabs
U.S. STOCKS ON THE MOVE-Meta Platforms, BlackBerry, Rivian Automotive, Cara Therapeutics
Adial Pharma rises on meeting FDA to advance lead drug development
Brief: Adial Pharmaceuticals Provides Update On Regulatory Strategy For AD04